Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032633 | 0.90 | HTT (0.48) | GAANR1H4HTTDAGLABDKRB1 | |
| SCHEMBL5803141 | 0.89 | VCAM1 (0.39) | GAANR1H4HTTDAGLAVCAM1 | |
| SCHEMBL642948 | 0.86 | GAA (0.48) | GAAHTTVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL5115197 | 0.85 | MCOLN3 (0.51) | GAAHTTVCAM1BDKRB1ALDH1A1 | |
| SCHEMBL5117215 | 0.84 | HTT (0.56) | GAAHTTALDH1A1L3MBTL1 | |
| SCHEMBL644589 | 0.84 | GAA (0.47) | GAAVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL5118024 | 0.83 | NR1H4 (0.48) | GAANR1H4HTTDAGLA | |
| SCHEMBL5800952 | 0.83 | L3MBTL1 (0.44) | HTTBDKRB1ALDH1A1L3MBTL1 | |
| SCHEMBL5111158 | 0.81 | MCOLN3 (0.52) | GAAHTTBDKRB1ALDH1A1L3MBTL1 | |
| SCHEMBL5114179 | 0.79 | PSEN1 (0.44) | GAANR1H4HTTDAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | claimed |
| WO-2006071775-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | claimed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2006071775-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | GAA 215/4885NR1H4 15/4885HTT 2903/4885 |
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | GAA 3390/4885NR1H4 314/4885HTT 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.